FDA releases a draft guidance entitled Good Review Management Principles and Practices for New Drug Applications and Biologics License Applications.
FDA releases a final guidance entitled ANDA Submissions Content and Format that details the information that should be provided in each section of th...
CDER director Janet Woodcock acknowledges that the pendulum has swung away from aggressive FDA drug advertising and promotion enforcement.
Federal Register notice: FDA announces an 11/15 Patient Engagement Advisory Committee meeting to discuss and make recommendations on the topic Connect...
CDER director Janet Woodcock says her top priorities include modernizing the new drug review program and hiring a permanent director for the Office of...
FDA awards 12 new clinical trial research grants totaling more than $18 million over the next four years to help develop medical products for patients...
FDA issues a final guidance entitled Benefit-Risk Factors to Consider When Determining Substantial Equivalence in Premarket Notifications (510(k)) wit...
FDA lifts a clinical hold against Sarepta Therapeutics against the companys Duchenne muscular dystrophy micro-dystrophin gene therapy program.